NIK-333

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
To improve the outcome of cancer chemotherapy, strategies to enhance the efficacy of anticancer drugs are required. Sorafenib is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
2012
2012
Development of an effective low-cost anti-acquired immunodeficiency syndrome (AIDS) drugs is needed for treatment of AIDS… Expand
  • figure 2
  • figure 3
  • figure 4
  • figure 6
  • figure 5
Is this relevant?
2011
2011
AIM   NIK-333 (an acyclic retinoid) has been reported to prevent recurrence of hepatocellular carcinoma (HCC) in patients after… Expand
Is this relevant?
2010
2010
The effect of an acyclic synthetic retinoid analogue NIK-333, on the restoration of liver mass and recovery of liver function… Expand
Is this relevant?
2009
2009
BACKGROUND & AIMS We previously reported that impaired retinoid signaling in the liver causes steatohepatitis and hepatocellular… Expand
  • figure 1
  • figure 2
  • figure 6
  • figure 4
  • figure 7
Is this relevant?
2007
2007
BACKGROUND In an attempt to develop effective and non-cytotoxic cancer chemopreventive derivatives of retinoids, a novel acyclic… Expand
Is this relevant?
2007
2007
The mechanisms of prevention of the development of liver cancer by NIK-333, an acyclic retinoid (ACR), were investigated. The… Expand
Is this relevant?
2006
2006
Adult T-cell leukemia (ATL) is caused by human T-cell leukemia virus type I (HTLV-I) and remains incurable. NIK-333, a novel… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2005
2005
We investigated the preventive effects of a synthetic acyclic retinoid, NIK-333, on the early and late events of… Expand
Is this relevant?
2004
2004
The present study was designed to determine the effects of NIK-333, a synthetic acyclic retinoid, on N-diethylnitrosamine (DEN… Expand
  • table I
  • figure 1
  • table II
  • table III
  • table IV
Is this relevant?